Alliqua ALQA entered into a
licensing agreement with Celgene Cellular Therapeutics (“CCT”), a
subsidiary of Celgene Corporation CELG (“Celgene”), whereby
Alliqua received the right to develop and market the advanced wound care
products Biovance® and Extracellular Matrix (ECM).
Concurrently with the license agreement, Alliqua entered into an
agreement with Celgene to sell to Celgene 1,672,474 shares of common
stock of Alliqua, at a purchase price of $3.59 per share and a five year
warrant to purchase an additional 836,237 shares of common stock at an
exercise price of $5.69, in exchange for $6.0 million. In connection
with this agreement to invest in Alliqua's securities, Celgene received
a right to appoint a director to Alliqua's Board
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in